NSGl 533/l NSG533l Examl 3l –l Advancedl
Pharmacologyl Review|l Wilkesl (Latestl
2026/l 2027l Update)l 100%l Verifiedl
Questionsl &l Answersl |l Gradel A
Q:l Bel surel tol recognizel thel nedl forl thel inhaledl corticosteroid:
Answer:
-ICSl arel thel mostl potentl anti-inflammatoryl agents
-theyl decreasel airwayl inflammation
-attenuatel airwayl hyper-responsivenessl
-minimizel mucusl productionl andl secretionsl
-theyl improvel thel actionsl ofl beta-agonistsl andl targetl thel lungsl directly
Q:l Bel surel tol recognizel thel riskl factorsl thatl mayl precipitatel anl asthmal attack:
Answer:
-uncontrolledl asthmal symptoms
-frequentl usel ofl SABA
-inadequatel ICSl therapyl
-lowl FEVl (<60%)l
-psychologicall orl financiall problemsl
-smokingl orl allergyl exposurel
, -obesity
-allergenl exposure
-pregnancy
-hxl ofl intubuationl
-1l orl morel exacerbationsl inl thel pastl year
Q:l Knowl whenl stepl downl therapyl canl bel initiatedl forl anl asthmatic:
Answer:
-oncel al patientl isl controlledl onl al maintenancel regimenl forl 3l monthsl withl nol symptoms
Q:l Knowl whichl betal blockersl arel notl anl absolutel contraindicationl forl anl asthmaticl
patient:
Answer:
betal 1:l cardioselectivel meds
atenolol,l metoprolol
Q:l Understandl thel mechanisml ofl actionl ofl thel beta-agonist:
Answer:
-thesel agentsl causel smoothl musclel relaxationl byl stimulatingl adenyll cyclasel tol increasel
formationl ofl cyclicl adenosinel monophosphatel (cAMP)
Pharmacologyl Review|l Wilkesl (Latestl
2026/l 2027l Update)l 100%l Verifiedl
Questionsl &l Answersl |l Gradel A
Q:l Bel surel tol recognizel thel nedl forl thel inhaledl corticosteroid:
Answer:
-ICSl arel thel mostl potentl anti-inflammatoryl agents
-theyl decreasel airwayl inflammation
-attenuatel airwayl hyper-responsivenessl
-minimizel mucusl productionl andl secretionsl
-theyl improvel thel actionsl ofl beta-agonistsl andl targetl thel lungsl directly
Q:l Bel surel tol recognizel thel riskl factorsl thatl mayl precipitatel anl asthmal attack:
Answer:
-uncontrolledl asthmal symptoms
-frequentl usel ofl SABA
-inadequatel ICSl therapyl
-lowl FEVl (<60%)l
-psychologicall orl financiall problemsl
-smokingl orl allergyl exposurel
, -obesity
-allergenl exposure
-pregnancy
-hxl ofl intubuationl
-1l orl morel exacerbationsl inl thel pastl year
Q:l Knowl whenl stepl downl therapyl canl bel initiatedl forl anl asthmatic:
Answer:
-oncel al patientl isl controlledl onl al maintenancel regimenl forl 3l monthsl withl nol symptoms
Q:l Knowl whichl betal blockersl arel notl anl absolutel contraindicationl forl anl asthmaticl
patient:
Answer:
betal 1:l cardioselectivel meds
atenolol,l metoprolol
Q:l Understandl thel mechanisml ofl actionl ofl thel beta-agonist:
Answer:
-thesel agentsl causel smoothl musclel relaxationl byl stimulatingl adenyll cyclasel tol increasel
formationl ofl cyclicl adenosinel monophosphatel (cAMP)
